Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Cystic Fibrosis Group To Support Pfizer R&D
by Lisa M. Jarvis
November 26, 2012
| A version of this story appeared in
Volume 90, Issue 48
Pfizer will receive up to $58 million in funding as part of a six-year pact with the Cystic Fibrosis Foundation. The money will support a preclinical research program devoted to finding compounds relevant to CF patients with a mutation in the Delta F508 gene. Almost 90% of CF patients have at least one copy of the Delta F508 mutation, which prevents CFTR, a protein critical for chloride ion transport, from reaching the surface of cells. Pfizer’s relationship with the foundation stems from its 2010 acquisition of FoldRx Pharmaceuticals, which had teamed with the nonprofit in 2007.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter